CAJ | 학술논문

目的观察5-羟色胺受体拮抗剂盐酸沙格雷酯对动脉硬化闭塞症膝下动脉腔内治疗术后后续治疗的疗效及安全性.方法选择我科2010年6月至2012年6月期间,动脉硬化闭塞症膝下动脉病变腔内治疗成功的105例患者(116条患肢),分为治疗组58例(64条患肢),对照组47例(52条患肢).腔内治疗术后,所有患者均长期口服阿司匹林,服用硫酸氢氯吡格雷3个月,治疗组加用盐酸沙格雷酯(口服100 mg 3次/d).观察间歇性跛行、静息痛、截肢情况、踝/肱指数(ankle brachial index,ABI)、治疗血管通畅率,肝肾功能变化及有无出血事件等.结果 105例患者中,共有95例(对照组43例,治疗组52例)患者经术后随访6个月,术后6个月治疗组及对照组间歇性跛行发生率分别为3.8％及16.3％;差异有统计学意义(P＜0.05);术后1、3个月间歇性跛行发生率、术后l、3、6个月静息痛发生率及截肢发生率差异无统计学意义(P＞0.05);术后治疗血管通畅率及治疗组踝肱指数(ankle brachial index,ABI)与同期对照组比较差异无统计学意义(P＞0.05).出血事件发生率1.7％.结论 5-羟色胺受体拮抗剂(盐酸沙格雷酯)对动脉硬化闭塞症膝下动脉腔内治疗术后间歇性跛行症状缓解存在一定作用,与阿司匹林及氯吡格雷联用的较安全.
목적 관찰5-간색알수체길항제염산사격뢰지대동맥경화폐새증슬하동맥강내치료술후후속치료적료효급안전성.방법 선택아과2010년6월지2012년6월기간,동맥경화폐새증슬하동맥병변강내치료성공적105례환자(116조환지),분위치료조58례(64조환지),대조조47례(52조환지).강내치료술후,소유환자균장기구복아사필림,복용류산경록필격뢰3개월,치료조가용염산사격뢰지(구복100 mg 3차/d).관찰간헐성파행、정식통、절지정황、과/굉지수(ankle brachial index,ABI)、치료혈관통창솔,간신공능변화급유무출혈사건등.결과 105례환자중,공유95례(대조조43례,치료조52례)환자경술후수방6개월,술후6개월치료조급대조조간헐성파행발생솔분별위3.8％급16.3％;차이유통계학의의(P＜0.05);술후1、3개월간헐성파행발생솔、술후l、3、6개월정식통발생솔급절지발생솔차이무통계학의의(P＞0.05);술후치료혈관통창솔급치료조과굉지수(ankle brachial index,ABI)여동기대조조비교차이무통계학의의(P＞0.05).출혈사건발생솔1.7％.결론 5-간색알수체길항제(염산사격뢰지)대동맥경화폐새증슬하동맥강내치료술후간헐성파행증상완해존재일정작용,여아사필림급록필격뢰련용적교안전.
Objective To evaluate a 5HT receptor antagonist sarpogrelate hydrochloride after percutaneous transluminal angioplasty (PTA) in infrapopliteal arteriosclerotic occlusive disease.Methods From June 2010 to June 2012,105 (116 limbs) patients of infrapopliteal arteriosclerosis obliterans treated by PTA were divided randomly into two groups:treatment group (58 cases,64 limbs)and control group(47 cases,52 limbs).All patients were treated with aspirin and clopidogrel for 3 months.Patients in treatment group were treated with additional sarpogrelate hydrochloride.Intermittent claudication,rest pain,amputation rate,ABI,vascular prosthesis obstructing degree were assessed.Results 95 patients were followed up for 6 months,the intermittent claudication rate in treatment group and control group were 3.8％ and 16.3％ (P ＜ 0.05); while there was not different on 1,3 months,in the intermittent claudication rate and 1,3,6 months,in rest pain rate,amputation rate,target artery patency rate and ABI between the two groups (P ＞ 0.05).There was one bleeding event in treatment group (1.7％).Conclusions 5HT receptor antagonist (sarpogrelate hydrochloride) significantly improves intermittent claudication after PTA in infrapopliteal arteriosclerotic occlusive disease,and its use is safe with aspirin and clopidogrel.